Written By: Todd Murphree, PharmD Clearview Cancer Institute
Download Here

Jakafi (ruxolitinib) is a selective Jak2 inhibitor used for the treatment of myelofibrosis (MF). This PQI will review the close monitoring of platelets required to ensure appropriate dose and avoid severe thrombocytopenia due to the therapy.
Continue reading Managing Myelofibrosis Patients

Read More